InvestorsHub Logo

crazyjogger925

07/20/21 6:43 PM

#175074 RE: stockorus #175065

even the renown dr bruce patterson opines re LL and ctc

CytoDyn advisor and diagnostic partner IncellD founder and CEO Bruce Patterson said: “Remarkably, the new patient enrolled in the clinical trial showed a significant drop in CTC and a reduction of EMT cells, the putative metastatic cells from seven per 4mL of blood to two cells in just two weeks of treatment with leronlimab in combination with carboplatin.

“The rapid response to the treatment in a pattern that is identical to previous patients is equally as remarkable and supports a predictable method of action for this drug. Additionally, no adverse effects were observed in the clinical trials, further supporting leronlimab’s potential safety profile.”

https://www.clinicaltrialsarena.com/news/cytodyn-results-leronlimab-mtnbc-mbc/

daemon57

07/20/21 6:54 PM

#175075 RE: stockorus #175065

Anyone having past communication with Dr. Recknor can send it to him.



Done, sent to CR. Thanks for posting stockorus.

GLTU/A.